Research
Energy balance
The mean change in body weight was -10.5% with semaglutide and -2.0% with placebo.
Semaglutide may lead to significant weight loss in patients with MASH.
StrongSupportsmedium confidence
The mean change in body weight was -10.5% with semaglutide and -2.0% with placebo.
Why this rating
Based on the large randomized controlled trial design.
Source
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
Arun J. Sanyal et al. · New England Journal of Medicine · 2025
DOI 10.1056/nejmoa2413258
rct · n=1197Cited 618×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Resolution of steatohepatitis without worsening of fibrosis occurred in 62.9% of the patients in the semaglutide group compared to 34.3% in the placebo group.Strong
- A reduction in liver fibrosis without worsening of steatohepatitis was reported in 36.8% of the patients in the semaglutide group compared to 22.4% in the placebo group.Strong
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →